Merck's New Phase 2b Trials
Merck has initiated three Phase 2b trials to evaluate the safety and efficacy of tulisokibart, an investigational monoclonal antibody targeting TL1A, in patients with hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis. These trials aim to enroll over 640 patients globally.
Ongoing Research
Tulisokibart is already in Phase 3 trials for ulcerative colitis and Crohn's disease. With the initiation of these new trials, tulisokibart is now being investigated in a total of six diseases, including systemic sclerosis-associated interstitial lung disease.
About Tulisokibart
Tulisokibart is a humanized monoclonal antibody directed at TL1A, associated with intestinal inflammation and fibrosis. It is thought to bind both soluble and membrane-bound TL1A, potentially inhibiting inflammatory pathways involved in inflammatory bowel disease and reducing intestinal fibrosis.
Target Diseases
Hidradenitis suppurativa is a chronic inflammatory skin condition affecting hair follicles, characterized by painful abscesses. Radiographic axial spondyloarthritis, also known as ankylosing spondylitis, involves chronic inflammation and pain in the spine and pelvis. Rheumatoid arthritis is a chronic autoimmune condition causing joint inflammation, pain, and stiffness, affecting millions globally.
